Floatz logo

Propaderm Forte

Chronic Eosinophilic Leukemia

Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Chronic Eosinophilic Leukemia cohort.

Asset / SponsorPhaseRating
Calcium Phosphate
Children's Oncology Group
Phase 3BB
Tacrolimus
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
Busulfanum
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B

View all 26 →

Same molecule, other indications

Propaderm Forte is also rated in:

plasma cell myelomaDormant
BB
Indicative · Phase 2
67 / 100
View asset →
graft versus host diseaseDormant
BB
Indicative · Phase 2
64 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative · Phase 2
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →